期刊文献+

115例华法林临床应用调查分析 被引量:22

An Investigation about the Clinical Application of Warfarin in 115 Patients
下载PDF
导出
摘要 目的了解我院住院患者华法林临床应用情况,总结临床用药经验,为临床用药提供参考,促进临床合理用药,探讨开展华法林临床药学监护的意义。方法查阅我院2009年1~12月应用华法林的住院患者病历115份,并对华法林临床应用的适应证、用药剂量、INR监测、出血并发症及合并用药等进行系统的回顾性调查分析。结果我院华法林的主要应用于心房颤动、深静脉血栓、起搏器或静脉支架植入术后等。住院患者华法林用量范围为0.625~7.5mg,平均日剂量2.45±0.81mg。INR波动于0.92~7.01。其中INR<1.5的病例占33.0%,INR为1.5~3.0的病例占44.3%,INR>3.0的病例占22.6%。华法林应用中出现出血并发症有尿潜血、脑出血、腰大肌出血,其总发生率为25.2%。出现出血并发症的病例中合并用药主要有抗凝药物、中成药、抗菌药物、胃黏膜保护药等。结论目前华法林的临床应用仍存在不足,积极开展华法林临床药学监护具有重要意义。临床药师将与医师一起共同创建安全、经济、有效的华法林用药体系。 Objective To investigate the clinical application of warfarin in patients of our hospital,summarize the experiences of its application,promote the rational use of warfarin.and probe the importance of the pharmaceutical care of warfarin.Methods 115 cases history of patients with warfarin in our hospital between 2009.1-2009.12 were consulted,to retrospectively analyze the indication,dosage,international normalized ratio(INR),hemorrhage event,and drugs used in combination with warfarin systematically.Results The common clinical indications for warfarin use were atrial fibrillation,deep vein thrombosis,cardiac pacemaker and venous stenting et al.The dosage of Warfarin used in patients was between 0.625-7.5mg.The average daily dosage was 2.45±0.81mg.The INR fluctuated between 0.92-7.01.The patients with INR1.5 accounted for 33.0%,the cases with INR between 1.5-3.0 accounted for 44.3%,and the cases with INR3.0 accounted for 22.6%.The hemorrhage events happened in patients with warfarin were hematuria,cerebral hemorrhage and psoas hemorrhage.Its incidence was 25.2%.The cases with hemorrhage commonly took warfarin combined with other drugs,such as anticoagulant drugs,Chinese patent medicines,antibacterials,gastric mucosal protective drugs.Conclusion At present,the clinical application of warfarin is still deficient.It is significant to develop the pharmaceutical care of warfarin activelic.The clinical pharmacists and physicians should make a concerted effort to build a safe,ecnomy and effective medication system for warfarin application.
出处 《中国药物警戒》 2011年第9期524-527,共4页 Chinese Journal of Pharmacovigilance
关键词 华法林 临床应用 调查分析 药学监护 warfarin clinical application investigation pharmaceutical care
  • 相关文献

参考文献14

二级参考文献46

  • 1周自强,胡大一,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量:1399
  • 2张学义,张薇,郑兆通,钟明,黎莉,张运.非瓣膜性心房颤动并发缺血性脑卒中的防治[J].中华急诊医学杂志,2004,13(9):592-594. 被引量:21
  • 3[1]Pharm ER. Differentiation of the low-molecule-weight heparines[J]. Pharmacotherapy, 2001,21(6pt2):62s. 被引量:1
  • 4[2]Merli G, Spiro TE, Olsson CG, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease[J]. Ann Intern Med, 2001,134:191. 被引量:1
  • 5[3]Hyers TM, Agnelli G, Hull RD, et al. Antithronboembolic therapy for venous thromboembolic disease[J]. Chest, 2001,119:176s. 被引量:1
  • 6[4]Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanism of action,pharmocokinetics,dosing, monitoring ,efficacy and safety[J]. Chest, 2001,119:64s. 被引量:1
  • 7[5]Bodgers GM. Thormbosis and antithrombotic therapy[M]. In:Lee GR. Foerster J, Lukens J. Wintorbes Clinic Haematology. 10th.Philadelphia: Lippincott Williams & Wildins, 1993:1 781~1 811. 被引量:1
  • 8Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the 被引量:1
  • 9Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest, 2001,119(1 Suppl):8S-21S. 被引量:1
  • 10Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest, 2001,119(1 Suppl):108S-121S. 被引量:1

共引文献927

同被引文献167

引证文献22

二级引证文献134

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部